Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Related studies linked through entity extraction aliases.